Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
42
MXCT Quote, Financials, Valuation and Earnings
Last price:
$1.51
Seasonality move
:
14.91%
Day range:
$1.48 - $1.53
52-week range:
$1.26 - $5.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.63x
P/B ratio:
0.89x
Volume:
1.7M
Avg. volume:
1.3M
1-year change:
-63.77%
Market cap:
$160M
Revenue:
$38.6M
EPS (TTM):
-$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MXCT
MaxCyte, Inc.
|
$8.8M | -$0.06 | 6.96% | -20.32% | $6.68 |
|
AXGN
Axogen, Inc.
|
$57.2M | $0.07 | 17.4% | 556.06% | $35.44 |
|
ELMD
Electromed, Inc.
|
$17.8M | -- | 11.04% | -- | $36.00 |
|
IRIX
IRIDEX Corp.
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo, Inc.
|
$10.8M | -$0.07 | -13.8% | -1168.66% | $5.00 |
|
STXS
Stereotaxis, Inc.
|
$9.2M | -$0.06 | 43.53% | -30.79% | $4.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MXCT
MaxCyte, Inc.
|
$1.50 | $6.68 | $160M | -- | $0.00 | 0% | 4.63x |
|
AXGN
Axogen, Inc.
|
$31.98 | $35.44 | $1.5B | -- | $0.00 | 0% | 7.09x |
|
ELMD
Electromed, Inc.
|
$28.62 | $36.00 | $238.7M | 30.79x | $0.00 | 0% | 3.82x |
|
IRIX
IRIDEX Corp.
|
$1.00 | -- | $17.2M | -- | $0.00 | 0% | 0.33x |
|
MYO
Myomo, Inc.
|
$0.93 | $5.00 | $35.8M | -- | $0.00 | 0% | 0.92x |
|
STXS
Stereotaxis, Inc.
|
$2.34 | $4.20 | $218.4M | -- | $0.00 | 0% | 6.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MXCT
MaxCyte, Inc.
|
9.15% | 0.035 | 10.78% | 7.08x |
|
AXGN
Axogen, Inc.
|
35.99% | -0.858 | 8.25% | 2.56x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
IRIX
IRIDEX Corp.
|
50.55% | 0.834 | 18.81% | 1.03x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
STXS
Stereotaxis, Inc.
|
32.62% | 1.831 | 1.93% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MXCT
MaxCyte, Inc.
|
$4.2M | -$11.2M | -21.09% | -23.05% | -164.65% | -$7.8M |
|
AXGN
Axogen, Inc.
|
$46M | $1.9M | -1.19% | -1.94% | 3.18% | $1.4M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
IRIX
IRIDEX Corp.
|
$4M | -$1.4M | -54.1% | -155.93% | -11.3% | -$1.2M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
STXS
Stereotaxis, Inc.
|
$4.1M | -$5.2M | -141.59% | -218.3% | -69.75% | -$4.2M |
MaxCyte, Inc. vs. Competitors
-
Which has Higher Returns MXCT or AXGN?
Axogen, Inc. has a net margin of -181.81% compared to MaxCyte, Inc.'s net margin of 1.18%. MaxCyte, Inc.'s return on equity of -23.05% beat Axogen, Inc.'s return on equity of -1.94%.
Company Gross Margin Earnings Per Share Invested Capital MXCTMaxCyte, Inc.61.34% -$0.12 $198.4M AXGNAxogen, Inc.76.55% $0.01 $188.7M -
What do Analysts Say About MXCT or AXGN?
MaxCyte, Inc. has a consensus price target of $6.68, signalling upside risk potential of 345.33%. On the other hand Axogen, Inc. has an analysts' consensus of $35.44 which suggests that it could grow by 10.83%. Given that MaxCyte, Inc. has higher upside potential than Axogen, Inc., analysts believe MaxCyte, Inc. is more attractive than Axogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MXCTMaxCyte, Inc.5 2 0 AXGNAxogen, Inc.7 0 0 -
Is MXCT or AXGN More Risky?
MaxCyte, Inc. has a beta of 0.310, which suggesting that the stock is 69.039% less volatile than S&P 500. In comparison Axogen, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.241%.
-
Which is a Better Dividend Stock MXCT or AXGN?
MaxCyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte, Inc. pays -- of its earnings as a dividend. Axogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MXCT or AXGN?
MaxCyte, Inc. quarterly revenues are $6.8M, which are smaller than Axogen, Inc. quarterly revenues of $60.1M. MaxCyte, Inc.'s net income of -$12.4M is lower than Axogen, Inc.'s net income of $708K. Notably, MaxCyte, Inc.'s price-to-earnings ratio is -- while Axogen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte, Inc. is 4.63x versus 7.09x for Axogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MXCTMaxCyte, Inc.4.63x -- $6.8M -$12.4M AXGNAxogen, Inc.7.09x -- $60.1M $708K
-
Which has Higher Returns MXCT or ELMD?
Electromed, Inc. has a net margin of -181.81% compared to MaxCyte, Inc.'s net margin of 12.65%. MaxCyte, Inc.'s return on equity of -23.05% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital MXCTMaxCyte, Inc.61.34% -$0.12 $198.4M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About MXCT or ELMD?
MaxCyte, Inc. has a consensus price target of $6.68, signalling upside risk potential of 345.33%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that MaxCyte, Inc. has higher upside potential than Electromed, Inc., analysts believe MaxCyte, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MXCTMaxCyte, Inc.5 2 0 ELMDElectromed, Inc.4 0 0 -
Is MXCT or ELMD More Risky?
MaxCyte, Inc. has a beta of 0.310, which suggesting that the stock is 69.039% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock MXCT or ELMD?
MaxCyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MXCT or ELMD?
MaxCyte, Inc. quarterly revenues are $6.8M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. MaxCyte, Inc.'s net income of -$12.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, MaxCyte, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte, Inc. is 4.63x versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MXCTMaxCyte, Inc.4.63x -- $6.8M -$12.4M ELMDElectromed, Inc.3.82x 30.79x $16.9M $2.1M
-
Which has Higher Returns MXCT or IRIX?
IRIDEX Corp. has a net margin of -181.81% compared to MaxCyte, Inc.'s net margin of -12.6%. MaxCyte, Inc.'s return on equity of -23.05% beat IRIDEX Corp.'s return on equity of -155.93%.
Company Gross Margin Earnings Per Share Invested Capital MXCTMaxCyte, Inc.61.34% -$0.12 $198.4M IRIXIRIDEX Corp.32.15% -$0.09 $9.5M -
What do Analysts Say About MXCT or IRIX?
MaxCyte, Inc. has a consensus price target of $6.68, signalling upside risk potential of 345.33%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 100%. Given that MaxCyte, Inc. has higher upside potential than IRIDEX Corp., analysts believe MaxCyte, Inc. is more attractive than IRIDEX Corp..
Company Buy Ratings Hold Ratings Sell Ratings MXCTMaxCyte, Inc.5 2 0 IRIXIRIDEX Corp.0 0 0 -
Is MXCT or IRIX More Risky?
MaxCyte, Inc. has a beta of 0.310, which suggesting that the stock is 69.039% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.
-
Which is a Better Dividend Stock MXCT or IRIX?
MaxCyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MXCT or IRIX?
MaxCyte, Inc. quarterly revenues are $6.8M, which are smaller than IRIDEX Corp. quarterly revenues of $12.5M. MaxCyte, Inc.'s net income of -$12.4M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, MaxCyte, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte, Inc. is 4.63x versus 0.33x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MXCTMaxCyte, Inc.4.63x -- $6.8M -$12.4M IRIXIRIDEX Corp.0.33x -- $12.5M -$1.6M
-
Which has Higher Returns MXCT or MYO?
Myomo, Inc. has a net margin of -181.81% compared to MaxCyte, Inc.'s net margin of -36.3%. MaxCyte, Inc.'s return on equity of -23.05% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital MXCTMaxCyte, Inc.61.34% -$0.12 $198.4M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About MXCT or MYO?
MaxCyte, Inc. has a consensus price target of $6.68, signalling upside risk potential of 345.33%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 436.19%. Given that Myomo, Inc. has higher upside potential than MaxCyte, Inc., analysts believe Myomo, Inc. is more attractive than MaxCyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MXCTMaxCyte, Inc.5 2 0 MYOMyomo, Inc.4 0 0 -
Is MXCT or MYO More Risky?
MaxCyte, Inc. has a beta of 0.310, which suggesting that the stock is 69.039% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock MXCT or MYO?
MaxCyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MXCT or MYO?
MaxCyte, Inc. quarterly revenues are $6.8M, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. MaxCyte, Inc.'s net income of -$12.4M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, MaxCyte, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte, Inc. is 4.63x versus 0.92x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MXCTMaxCyte, Inc.4.63x -- $6.8M -$12.4M MYOMyomo, Inc.0.92x -- $10.1M -$3.7M
-
Which has Higher Returns MXCT or STXS?
Stereotaxis, Inc. has a net margin of -181.81% compared to MaxCyte, Inc.'s net margin of -86.59%. MaxCyte, Inc.'s return on equity of -23.05% beat Stereotaxis, Inc.'s return on equity of -218.3%.
Company Gross Margin Earnings Per Share Invested Capital MXCTMaxCyte, Inc.61.34% -$0.12 $198.4M STXSStereotaxis, Inc.54.94% -$0.07 $17.1M -
What do Analysts Say About MXCT or STXS?
MaxCyte, Inc. has a consensus price target of $6.68, signalling upside risk potential of 345.33%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 79.49%. Given that MaxCyte, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe MaxCyte, Inc. is more attractive than Stereotaxis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MXCTMaxCyte, Inc.5 2 0 STXSStereotaxis, Inc.3 0 0 -
Is MXCT or STXS More Risky?
MaxCyte, Inc. has a beta of 0.310, which suggesting that the stock is 69.039% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.
-
Which is a Better Dividend Stock MXCT or STXS?
MaxCyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MaxCyte, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MXCT or STXS?
MaxCyte, Inc. quarterly revenues are $6.8M, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. MaxCyte, Inc.'s net income of -$12.4M is lower than Stereotaxis, Inc.'s net income of -$6.5M. Notably, MaxCyte, Inc.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MaxCyte, Inc. is 4.63x versus 6.90x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MXCTMaxCyte, Inc.4.63x -- $6.8M -$12.4M STXSStereotaxis, Inc.6.90x -- $7.5M -$6.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
